MyFinsight
Home
About
Contact
amph: the income statement
Download
Download image
Other Products
$64,145K
Lidocaine
$12,932K
Epinephrine
$18,789K
Glucagon
$13,558K
Primatenemist
$28,808K
Baqsimi
$53,608K
Revenues
$191,840K
(0.33%↑ Y/Y)
Gross profit
$98,646K
(-3.23%↓ Y/Y)
Cost of revenues
$93,194K
(4.39%↑ Y/Y)
Income from operations
$25,320K
(-55.62%↓ Y/Y)
Total operating
expenses
$73,326K
(63.34%↑ Y/Y)
Income before income
taxes
$21,513K
(-54.88%↓ Y/Y)
Total non-operating
income (expenses), net
-$3,807K
(59.35%↑ Y/Y)
Other income
(expenses), net
$231K
(104.53%↑ Y/Y)
Interest income
$2,246K
(-7.46%↓ Y/Y)
Research and development
$22,354K
(6.06%↑ Y/Y)
General and
administrative
$39,467K
(166.29%↑ Y/Y)
Selling, distribution,
and marketing
$11,505K
(27.90%↑ Y/Y)
Income before equity in
losses of...
$17,350K
(-57.09%↓ Y/Y)
Income tax provision
$4,163K
(-42.61%↓ Y/Y)
Interest expense
$6,284K
(-6.18%↓ Y/Y)
Net income
$17,350K
Back
Back
Income Statement
source: myfinsight.com
Amphastar Pharmaceuticals, Inc. (AMPH)
Amphastar Pharmaceuticals, Inc. (AMPH)